FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

FDA OKs Bristol-Myers Squibb's Breyanzi To Treat Large-B-Cell Lymphoma

BMS' CAR-T pressures Gilead in 2L lymphoma with broader nod

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bryan Bloom, Author at NJBIZ

Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision

New COVID-19 relief package would allow cannabiz banking and insurance - NJBIZ

Bristol Myers Squibb's Reblozyl, chasing $4B sales target, wins key FDA label expansion

Bristol Myers Squibb - Recent News & Activity

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

CBRE: Northeast industrial markets demonstrate resiliency - NJBIZ

Cushman & Wakefield named exclusive agent for Morristown office asset - NJBIZ

Carlyle buying broadcasting, streaming firm LiveU for $400M - NJBIZ

NJ companies give, and get, COVID-19 donations - NJBIZ

Lee & Associates New Jersey relocates to Elmwood Park - NJBIZ

Bristol-Myers Squibb Baraclude Patient Assistance - Needy Meds